The last step to achieve barrier damage control

Ilaria Baglivo, Stefania Colantuono, Arianna Lumaca, Alfredo Papa, Antonio Gasbarrini, Cristiano Caruso

Risultato della ricerca: Contributo in rivistaAbstract


Heterogeneity characterises inflammatory diseases and different phenotypes and endotypes have been identified. Both innate and adaptive immunity contribute to the immunopathological mechanism of these diseases and barrier damage plays a prominent role triggering type 2 inflammation through the alarmins system, such as anti-Thymic Stromal Lymphopoietin (TSLP). Treatment with anti-TSLP monoclonal antibodies showed efficacy in severe asthma and clinical trials for other eosinophilic diseases are ongoing. The aim of this perspective review is to analyse current advances and future applications of TSLP inhibition to control barrier damage.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaFrontiers in Immunology
Stato di pubblicazionePubblicato - 2024


  • alarmins
  • eosinophils
  • epithelial barrier damage
  • immune system
  • non-T2 inflammation
  • tezepelumab
  • type 2 inflammation


Entra nei temi di ricerca di 'The last step to achieve barrier damage control'. Insieme formano una fingerprint unica.

Cita questo